HER2-targeted drug with radiation for non-surgical solid cancers
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests a HER2-targeted antibody drug (RC48-ADC) given with radiation in people with locally advanced solid tumors that cannot be removed by surgery. It aims to find a safe way to use the treatment and see how well it works in cancers that have HER2 protein on their cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign informed consent.
- Your cancer is locally advanced, not removable by surgery, and standard chemotherapy plus radiation is not an option (or you’re not eligible/refuse it).
- Your tumor tests positive for HER2 (IHC 1+, 2+, or 3+ from lab testing at the study site).
- You have at least one measurable tumor spot on scans, and your overall health is good (ECOG 0 or 1).
- You have not had any prior radiation or anti-cancer medicines for this locally advanced cancer.
- Your blood counts and organ function tests are strong enough for treatment (heart, liver, kidneys, and bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
This trial tests whether combining the drug RC48 with chemotherapy can help people whose HER2-positive advanced breast cancer has stopped responding to a prior type of antibody-drug conjugate (ADC) therapy. It may offer a new treatment option for those whose cancer has progressed after previous treatments.
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
This trial tests an investigational drug called Disitamab Vedotin for people with advanced Paget's disease that tests positive for HER2. It aims to see if the drug can shrink tumors or improve skin lesions.
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.